SCM
ABOS icon

Sterling Capital Management’s Acumen Pharmaceuticals ABOS Stock Holding History

Sterling Capital Management’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.54K Buy
+952
New +$2.35K ﹤0.01% 2922
2025
Q2 		– Sell
-685
Closed -$754 – 3264
2025
Q1 		$754 Sell
685
-740
-52% -$1.06K ﹤0.01% 2894
2024
Q4 		$2.45K Buy
1,425
+1,292
+971% +$3.11K ﹤0.01% 2726
2024
Q3 		$330 Buy
+133
New +$361 ﹤0.01% 3010

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $1.12B AUM 41.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Sterling Capital Management's ABOS Position: Q2 2026 in Review

Sterling Capital Management opened a new position in Acumen Pharmaceuticals (ABOS) in Q2 2026: 952 shares worth $2.54K. The stake represents ﹤0.01% of the portfolio and ranks #2922 among its holdings. This is a return to the name: Sterling Capital Management previously reported a position in ABOS as recently as Q1 2025.

Sterling Capital Management first reported a position in ABOS in Q3 2024 and has held it in 4 quarters since. 96 funds tracked by Wall St. Rank hold ABOS as of Q2 2026.

  • Sterling Capital Management held 952 shares of Acumen Pharmaceuticals worth $2.54K as of Q2 2026.
  • Acumen Pharmaceuticals was a new Sterling Capital Management position in Q2 2026.
  • Acumen Pharmaceuticals made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #2922 holding.
  • Sterling Capital Management first reported a position in Acumen Pharmaceuticals in Q3 2024 and has held it in 4 quarters since.
  • 96 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.